CliffBio
biologic

Repatha

evolocumab

Loss of exclusivityAugust 2027projected — 12-year biologic exclusivity estimate
CompanyAmgen →See this company's full patent-cliff portfolio

Drug detail

Brand nameRepatha
Active ingredientevolocumab
Strength140MG/ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalAugust 2015
Marketing statusRx

More from Amgen

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Repatha patent cliff — loss of exclusivity August 2027 | CliffBio